Prescription medicine
Indium in -111 pentetreotide Brand names: Octreoscan
Indium in -111 pentetreotide (Octreoscan) is a prescription medicine. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the indium in -111 pentetreotide FDA label on DailyMed (effective February 21, 2022); every indium in -111 pentetreotide label on DailyMed.
Highlights of the record
FDA label of February 21, 2022; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageOctreoscan, after radiolabeling, is an agent for the scintigraphic localization of primary and metastatic neuroendocrine tumors bearing somatostatin receptors.
Forms and strengths
Kit.
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 128 through July 30, 2026
What is indium in -111 pentetreotide used for?
From the label: indications and usageOctreoscan, after radiolabeling, is an agent for the scintigraphic localization of primary and metastatic neuroendocrine tumors bearing somatostatin receptors.
Source: FDA drug label (OCTREOSCAN), Curium US LLC, effective February 21, 2022 (SPL set 93d8f3b2-1216-41dc-a63d-0e812b33891d), via openFDA; the full label on DailyMed
Is there a generic for indium in -111 pentetreotide (Octreoscan)?
No generic indium in -111 pentetreotide is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the indium in -111 pentetreotide label say about other medicines?
The indium in -111 pentetreotide label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Octreotide | warnings | IN THESE SOLUTIONS, A COMPLEX GLYCOSYL OCTREOTIDE CONJUGATE MAY FORM. |
Source: FDA drug label (OCTREOSCAN), Curium US LLC, effective February 21, 2022 (SPL set 93d8f3b2-1216-41dc-a63d-0e812b33891d), via openFDA; the full label on DailyMed
What do FAERS reports show for indium in -111 pentetreotide?
The FDA Adverse Event Reporting System holds 128 reports that list indium in -111 pentetreotide among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 42 are coded as a death and 23 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Indium in -111 pentetreotide side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other